Clinical studies have demonstrated that some antihypertensive agents provide renoprotection independent of BP lowering. Recent in vitro and in vivo studies evaluated the mechanisms involved in this protection. First, the in vitro effects of several angiotensin II type 1 receptor blockers (ARB), calcium channel blockers (CCB), and  blockers (BB) on various mediators were compared: Formation of pentosidine (an advanced glycation end product), hydroxyl radical-induced formation of o-tyrosine, and transition metals-induced oxidation of ascorbic acid (the Fenton reaction). All of the six tested ARB but neither the six CCB nor the nine BB inhibited pentosidine formation. ARB, as well as BB but not CCB, inhibited hydroxyl radicals-mediated o-tyrosine formation. ARB but neither BB nor CCB inhibited efficiently transition metals-catalyzed oxidation of ascorbic acid. Second, the in vivo consequences for the kidney of these various in vitro effects were evaluated. Hypertensive, type 2 diabetic rats with nephropathy, SHR/NDmcr-cp, were given for 20 wk either olmesartan (ARB) or nifedipine (CCB), or atenolol (BB). Despite similar BP reduction, only ARB significantly reduced proteinuria and prevented glomerular and tubulointerstitial damage (mesangial activation, podocyte injury, tubulointerstitial injury, and inflammatory cell infiltration). It is interesting that only ARB prevented abnormal iron deposition in the interstitium, corrected chronic hypoxia, reduced expressions of heme oxygenase and p47phox (a subunit of NADPHoxidase), and inhibited pentosidine formation (which correlates well with proteinuria). These observations confirm unique renoprotective properties of ARB, independent of BP lowering but related to decreased oxidative stress (hydroxyl radicals scavenging and inhibition of the Fenton reaction), correction of chronic hypoxia, and inhibition of advanced glycation end product formation and of abnormal iron deposition. These benefits of ARB may contribute to the renoprotection observed beyond BP lowering. S everal clinical studies, mainly but not only in diabetic patients, have provided evidence that some antihypertensive agents that inhibit the renin-angiotensin system (RAS), namely angiotensin II type 1 receptor blockers (ARB) and angiotensin-converting enzyme inhibitors (ACEI), are renoprotective (1-4). Recently, the renoprotection provided by these drugs seems at least partly independent of BP lowering and related perhaps to the inhibition of the RAS (5-8). ARB and ACEI thus now are part of the standard treatment of patients with diabetic nephropathy, regardless of the presence of systemic hypertension. A similar renoprotective effect has been claimed for nifedipine or other calcium channel blockers (CCB) acting independent of the RAS (9,10), but results of clinical studies remain disputed (5).The nature of the renoprotection provided by some antihypertensive agents independent of BP lowering and inhibition of the RAS thus has become a topic of major interest. We previously demonstrated in vitro that ARB an...